Hormonal regulation of Semaphorin 7a in ER+ breast cancer drives therapeutic resistance
L. S. Crump, G. L. Wyatt, T. R. Rutherford, J. K. Richer, W. W. Porter, T. R. Lyons
This study identifies SEMA7A as a driver of therapeutic resistance in ER+ breast cancer and suggests targeting survival signaling pathways as a potential treatment strategy.
bioRxiv · Oct 5, 2020Cancer Biology